CD137 is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB and induced by lymphocyte activation (ILA). It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule.
CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4T cells. In addition, CD137 expression is found on dendritic cells, B cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation.
Specific effects on cells
The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice.
Utomilumab (PF-05082566) targets this receptor to stimulate a more intense immune system attack on cancers.[3] It is a fully human IgG2 monoclonal antibody.[4] It is in early clinical trials.[3] As of June 2016[update] 5 clinical trials are active.[5]
Schwarz H, Tuckwell J, Lotz M (1993). "A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family". Gene. 134 (2): 295–8. doi:10.1016/0378-1119(93)90110-O. PMID8262389.
Sica G, Chen L (2000). "Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy". Arch. Immunol. Ther. Exp. (Warsz.). 47 (5): 275–9. PMID10604232.
Schwarz H (2005). "Biological activities of reverse signal transduction through CD137 ligand". J. Leukoc. Biol. 77 (3): 281–6. doi:10.1189/jlb.0904558. PMID15618293.
Zhou Z, Kim S, Hurtado J, Lee ZH, Kim KK, Pollok KE, Kwon BS (1995). "Characterization of human homologue of 4-1BB and its ligand". Immunol. Lett. 45 (1–2): 67–73. doi:10.1016/0165-2478(94)00227-I. PMID7622190.
Alderson MR, Smith CA, Tough TW, Davis-Smith T, Armitage RJ, Falk B, Roux E, Baker E, Sutherland GR, Din WS (1994). "Molecular and biological characterization of human 4-1BB and its ligand". Eur. J. Immunol. 24 (9): 2219–27. doi:10.1002/eji.1830240943. PMID8088337.
Schwarz H, Tuckwell J, Lotz M (1994). "A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family". Gene. 134 (2): 295–8. doi:10.1016/0378-1119(93)90110-O. PMID8262389.
Schwarz H, Blanco FJ, von Kempis J, Valbracht J, Lotz M (1996). "ILA, a member of the human nerve growth factor/tumor necrosis factor receptor family, regulates T-lymphocyte proliferation and survival". Blood. 87 (7): 2839–45. PMID8639902.
Loo DT, Chalupny NJ, Bajorath J, Shuford WW, Mittler RS, Aruffo A (1997). "Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB". J. Biol. Chem. 272 (10): 6448–56. doi:10.1074/jbc.272.10.6448. PMID9045669.
Schwarz H, Arden K, Lotz M (1997). "CD137, a member of the tumor necrosis factor receptor family, is located on chromosome 1p36, in a cluster of related genes, and colocalizes with several malignancies". Biochem. Biophys. Res. Commun. 235 (3): 699–703. doi:10.1006/bbrc.1997.6870. PMID9207223.
Jang IK, Lee ZH, Kim YJ, Kim SH, Kwon BS (1998). "Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B". Biochem. Biophys. Res. Commun. 242 (3): 613–20. doi:10.1006/bbrc.1997.8016. PMID9464265.
Langstein J, Michel J, Schwarz H (1999). "CD137 induces proliferation and endomitosis in monocytes". Blood. 94 (9): 3161–8. PMID10556203.
Jang LK, Lee ZH, Kim HH, Hill JM, Kim JD, Kwon BS (2002). "A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction". Mol. Cells. 12 (3): 304–12. PMID11804328.
Cooper D, Bansal-Pakala P, Croft M (2002). "4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity". Eur. J. Immunol. 32 (2): 521–9. doi:10.1002/1521-4141(200202)32:2<521::AID-IMMU521>3.0.CO;2-X. PMID11828369.
Wilcox RA, Chapoval AI, Gorski KS, Otsuji M, Shin T, Flies DB, Tamada K, Mittler RS, Tsuchiya H, Pardoll DM, Chen L (2002). "Cutting edge: Expression of functional CD137 receptor by dendritic cells". J. Immunol. 168 (9): 4262–7. doi:10.4049/jimmunol.168.9.4262. PMID11970964.
Shulzhenko N, Morgun A, Chinellato AP, Rampim GF, Diniz RV, Almeida DR, Gerbase-DeLima M (2002). "CD27 but not CD70 and 4-1BB intragraft gene expression is a risk factor for acute cardiac allograft rejection in humans". Transplant. Proc. 34 (2): 474–5. doi:10.1016/S0041-1345(02)02600-3. PMID12009595.
Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H (2002). "CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers". J. Leukoc. Biol. 72 (1): 35–42. PMID12101260.